CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-09). The draft was written by AI, all 4 cited sources were opened and checked for existence, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 138 · Search date 2026-07-09 · Methodology v0.6

PQQ,
does it really help with Energy and cognition?

30-Second Summary
?
Evidence Grade ? · Safety caution
Human efficacy evidence is still insufficient to grade.
What the
research shows
PQQ still lacks direct human evidence sufficient to grade energy and cognition improvement from A to F. Current human data center on subjective questionnaires and blood markers, so the conclusion is Judgment deferred, not no effect.
What the
ads claim
Advertising emphasizes 'mitochondrial booster,' 'cellular energy,' 'antioxidant,' 'brain energy,' and 'synergy with CoQ10.' A substantial part of these expressions is closer to mechanistic or surrogate-marker evidence.
*

Useful facts when choosing a product

  • Commercial doses of 10-20 mg/day are common, and many studies are also in this range.
  • Safety data should be distinguished by ingredient form, such as PQQ disodium salt.
  • Mitochondrial biogenesis and inflammation markers are not the same as clinical fatigue or cognitive improvement.
  • Long-term high-dose safety data are limited.
Gap Measurement · Verdict 138 · ?
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Small human studies such as Nakano 2012 reported changes in stress, fatigue, and sleep questionnaires after PQQ intake. Harris 2013 evaluated blood markers related to inflammation and mitochondria, but it was not a direct study of clinical energy or cognitive improvement. Even if some cognitive subtest signals have been reported, sample size and independent replication are limited. Because the current evidence centers on subjective questionnaires and surrogate markers, it is difficult to confirm the energy and cognition efficacy of PQQ as a supplement or to score it as grade C.

02

Why this is classified as ?

PQQ evidence mixes preclinical and mechanistic hypotheses, safety reviews, and small subjective-questionnaire or blood-marker studies. However, there is no confirmatory RCT using objective clinical endpoints for energy or cognitive improvement, so no A-F grade or score is assigned. The current conclusion is not no effect, but Judgment deferred, meaning evidence is insufficient to judge.

Counterpoint. Regulatory safety review is not evidence of efficacy, and 'mitochondrial' mechanistic claims must be verified separately from felt energy or cognitive-improvement claims.

Rejudgment record. Final judgment by lead Claude — A-F grading is deferred because evidence centers on subjective questionnaires and blood markers, with no confirmatory RCT for objective energy or cognition clinical endpoints.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Nakano M et al. 2012Small human study17Possible industry tiesStress, fatigue, and sleep questionnairesReported questionnaire improvements after PQQ intake, but design limitations were substantial.Supporting
Study 2Randomized placebo-controlled trialPossible ingredient-industry tiesCognitive testsReported signals in some cognitive subtests, but independent replication is limited.Supporting
Harris CB et al. 2013Human metabolic-marker study10Possible industry tiesInflammation and mitochondria-related markersBlood metabolic-marker changes were observed, but these were not clinical energy or cognition endpoints.Surrogate marker
Study 4Regulatory materialOfficial/application dataSafetyReviewed the safety of a specific PQQ disodium salt ingredient under conditions of use.Safety
§

Receipt — 4 References

Every cited source was opened and checked against the live page on 2026-07-09.

Nakano M, et al. Effects of oral supplementation with pyrroloquinoline quinone on stress, fatigue, and sleep. Funct Foods Health Dis. 2012.
checked
Harris CB, et al. Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects. J Nutr Biochem. 2013.
checked
Ames BN. Prolonging healthy aging: Longevity vitamins and proteins. Proc Natl Acad Sci USA. 2018.
checked
EFSA NDA Panel. Safety of pyrroloquinoline quinone disodium salt as a novel food. EFSA Journal.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-09 · Corrections: none

Cite this verdict

PQQ x energy and cognition Evidence Grade ? card
[Chamgap] PQQ x energy and cognition — Evidence Grade ?. 4 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/energy/pqq-energy-cognition/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.